Warren Buffett. Image source: The Motley Fool.
Since the beginning of 2016, Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) has seen the value of the seven bank stocks in its investment portfolio increase by $5.6 billion, or 10.8%.
That’s a lot of money, butwhen you compare it to how blue-chip bank stocks performed more generally, something interesting sticks out. While Berkshire’s portfolio of bank stocks outperformed the S&P 500 this year, it underperformed the main index that tracks bank stocks.
The drag on Buffett’s bank stocks
You can see this by looking at the KBW Bank Index, which tracks two dozen of the nation’s leading bank stocks. It’s up 26.4% this year. That’s more than twice the gain Berkshire Hathaway has seen on its bank holdings.
What’s the deal? The answer is that not all of the bank stocks selected by Warren Buffett for Berkshire Hathaway’s portfolio performed equally well this year. One in particular dragged down its returns: Wells Fargo (NYSE:WFC).
Best Warren Buffett Stocks To Own Right Now: Genomic Health, Inc.(GHDX)
Advisors’ Opinion:
- [By Brian Orelli]
Cancer-test maker Genomic Health (NASDAQ:GHDX) started the year on a high note, posting double-digit revenue growth, and would have turned a profit if not for an $8.5 millionone-time charge for stopping development of the Oncotype SEQ Liquid Select test, which was announced on the last quarterly call.
- [By Shane Hupp]
Genomic Health (NASDAQ: GHDX) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
- [By Logan Wallace]
Genomic Health (NASDAQ:GHDX) – Equities researchers at Piper Jaffray issued their Q2 2018 earnings per share (EPS) estimates for shares of Genomic Health in a research report issued on Wednesday, May 2nd. Piper Jaffray analyst W. Quirk expects that the medical research company will post earnings of $0.06 per share for the quarter. Piper Jaffray has a “Hold” rating and a $33.00 price target on the stock. Piper Jaffray also issued estimates for Genomic Health’s Q3 2018 earnings at $0.11 EPS, Q4 2018 earnings at $0.14 EPS, FY2018 earnings at $0.44 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.12 EPS, Q4 2019 earnings at $0.15 EPS and FY2019 earnings at $0.62 EPS.
- [By Stephan Byrd]
ELEKTA AB/ADR (OTCMKTS: EKTAY) and Genomic Health (NASDAQ:GHDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
- [By Logan Wallace]
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Get Genomic Health alerts:
Zacks: Brokerages Expect Genomic Health, Inc. (GHDX) to Post $0.07 EPS (americanbankingnews.com) BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5% (finance.yahoo.com) Genomic Health (GHDX) vs. Veracyte (VCYT) Head-To-Head Contrast (americanbankingnews.com) PetMed (PETS) Optimistic About New Orders Amid Cost Woes (finance.yahoo.com) Genomic Health Inc. (GHDX) PT Raised to $56 at Canaccord Genuity (streetinsider.com)
Genomic Health stock traded up $0.57 during mid-day trading on Wednesday, hitting $50.58. 868 shares of the company’s stock were exchanged, compared to its average volume of 337,252. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 5,058.00 and a beta of 0.64. Genomic Health has a 1-year low of $26.54 and a 1-year high of $53.65.
- [By Stephan Byrd]
Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $48.89, for a total value of $488,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Best Warren Buffett Stocks To Own Right Now: Oak Valley Bancorp (CA)(OVLY)
Advisors’ Opinion:
- [By Shane Hupp]
Oak Valley Bancorp (NASDAQ:OVLY) Director H Randolph Holder, Jr. purchased 3,200 shares of the business’s stock in a transaction on Friday, May 18th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $64,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Best Warren Buffett Stocks To Own Right Now: Datawatch Corporation(DWCH)
Advisors’ Opinion:
- [By Lisa Levin]
On Thursday, the information technology shares surged 0.29 percent. Meanwhile, top gainers in the sector included Keysight Technologies, Inc. (NYSE: KEYS), up 12 percent, and Datawatch Corporation (NASDAQ: DWCH) up 6 percent.
Best Warren Buffett Stocks To Own Right Now: OpGen, Inc.(OPGN)
Advisors’ Opinion:
- [By Lisa Levin]
OpGen, Inc. (NASDAQ: OPGN) shares shot up 19 percent to $2.50. OpGen completed rapid testing clinical trial in Colombia and expanded international operations.
- [By Max Byerly]
OpGen (NASDAQ: OPGN) and Cancer Genetics (NASDAQ:CGIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
- [By Shane Hupp]
Get a free copy of the Zacks research report on OpGen (OPGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
OpGen, Inc. (NASDAQ: OPGN) shares shot up 15 percent to $2.41. OpGen completed rapid testing clinical trial in Colombia and expanded international operations.
Best Warren Buffett Stocks To Own Right Now: Standex International Corporation(SXI)
Advisors’ Opinion:
- [By Logan Wallace]
Barclays PLC boosted its holdings in Standex Int’l Corp. (NYSE:SXI) by 13.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,804 shares of the industrial products company’s stock after buying an additional 561 shares during the period. Barclays PLC’s holdings in Standex Int’l were worth $459,000 as of its most recent SEC filing.
- [By Stephan Byrd]
Synex International (TSE:SXI) Director Glenn Stanley Mcdonnell sold 250,000 shares of the stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of C$0.50, for a total transaction of C$125,000.00.